Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 1
Abstract
It is a comment of an article published in N Engl J Med. 2008;359:2429-41
Authors and Affiliations
Mazhar Haque, Eric Yoshida
Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis
Objective. Angiotensin II, one component of renin-angiotensin system (RAS), is formed from Ang I by the catalysing of angiotensin converting enzyme (ACE). Angiotensin II plays an important role in the development of insu...
Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis
Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins, may reduce the incidence of various tumors, including HCC. Antitumoral activities may be mediated by changes in transforming growth factor-beta (TGF...
Non-neoplastic Portal Vein Thrombosis in HCV Cirrhosis Patients: Is it an Immuno-Inflammatory Disorder?
Background and aims. Portal vein thrombosis (PVT) is a critical complication in cirrhotic patients. We explored the role of the activated factor VII-antithrombin (FVIIa-AT) complex and enhanced monocytic tissue factor (T...
Acute kidney injury after liver transplantation is associated with viral hepatitis, prolonged warm ischemia, serum lactate and higher mortality
Serum cystatin C measurement in differential diagnosis of intra and extrahepatic cholestatic diseases
Objective. Cystatin C is a very potent inhibitor of cysteine proteinases and, it has been clinically applied as a sensitive marker in monitoring of renal and liver functions. The aim of this study was to reveal whether...